Al-Jebari Y, et al. - Through a nationwide register study in Sweden from 1994–2014 on 2,027,997 people, the contributors sought to investigate additional congenital malformations (CMs) risk possibilities post anti-neoplastic treatment for testicular germ-cell cancer (TGCC). Lack of data on the use of cryopreserved or donor sperm and on seminoma patients for the period 1995–2000; and the power of analyses on chemotherapy intensity and radiotherapy was the limitation of this study. In children of men with TGCC treated with radio- or chemotherapy, no extra CMs risks were noted. Although, modestly increased risk for offspring malformations was correlated with paternal TGCC per se.